Most of us have recently heard a great deal about how vaccines help protect against the serious effects of COVID-19. But did you know that vaccines can also be used to treat disease?

A new partnership between Ovarian Cancer Canada and the Cancer Research Society recently announced funding for 10 new projects testing treatments that show potential to help people with this disease live longer and better.

Dr. Mark Carey is developing scientific models to advance research on low-grade serous cancer, a rare form of the disease.

IRICoR and Ovarian Cancer Canada announce $2.3M for development of new treatments for ovarian cancer

The Cancer Research Society and Ovarian Cancer Canada are proud to jointly launch a competition to fund some of Canada’s most promising research projects focused on ovarian cancer. The competition will award up to 6 grants, each totaling $225,000 over a two-year period.

These will enable scientists to test new treatments, leading to new clinical trials, and ultimately improved outcomes for women with this disease.

OvCAN Patient Partners have important roles in a wide range of activities, from reviewing clinical trial funding applications to sharing their lived experience directly with ovarian cancer researchers and scientists.

Dr. Kirk McManus and Dr. Mark Nachtigal's collaborative research project was recently awarded two years’ joint funding from Ovarian Cancer Canada and the Cancer Research Society.

Four OvCAN-funded clinical trials happening across Canada will provide a wide range of new insights.